Pharma BD Deal Intelligence
LabCorp's $925M cash acquisition of Genzyme Genetics anchored a reproductive- and oncology-genetic-testing franchise LabCorp still runs today, though the category proved a treadmill: LabCorp had to keep buying (Sequenom in 2016) to stay competitive in prenatal testing, and that later acquisition has since saddled the business with a confirmed ~$372.5M patent judgment.
Zacks framed the $925M acquisition as a sound strategic fit that meaningfully expanded LabCorp's reproductive, hematology-oncology, and clinical-trials…
The FTC challenged a separate LabCorp acquisition (Westcliff) the same year, signaling regulatory scrutiny of the duopolistic LabCorp/Quest market position…
LabCorp confirmed close on December 1, 2010, citing immediate accretion to esoteric/molecular testing capacity and ~$795M net cash cost after tax benefits.
Source summaries from our enrichment pipeline; follow links for originals.
All 5 sources with sentiment breakdown →
LabCorp agreed to acquire Genzyme's Genetics business for $925M cash. 2009 revenue ~$371M with 9 testing labs and ~1,900 employees. Closed December 1, 2010.
Assessment window: 10yr post-close.
$371M Genzyme Genetics 2009 revenue
Specialty genetic and pathology testing covers prenatal/reproductive (carrier screening, chromosomal microarrays, NIPT precursors), hematology-oncology (FISH, cytogenetics, molecular markers), and clinical-trial central lab services. These higher-complexity, higher-margin esoteric tests sit above routine clinical chemistry in the lab value chain and are concentrated among a small number of national reference labs.
By 2010, US clinical lab testing was a duopoly: LabCorp and Quest Diagnostics together held roughly 89% of the national reference market. Both were aggressively acquiring esoteric and molecular labs to defend against in-sourcing by hospitals/IDNs and decentralized point-of-care players. Quest had bought AmeriPath in 2007 (~2.5x revenue) for anatomic pathology; LabCorp's $925M Genzyme Genetics buy (also ~2.5x revenue) directly mirrored that move on the genetic/molecular side. Genzyme Genetics — being divested by Sanofi-acquired Genzyme to refocus on rare-disease therapeutics — was the preferred reproductive-testing provider to maternal-fetal medicine specialists and OB/GYNs nationally, with double-digit growth in a 70/30 prenatal/onc-heme test mix. The deal added 9 labs and ~1,900 employees, expanded LabCorp's clinical-trials central-lab footprint, and slotted directly into the company's esoteric/molecular pivot. Avondale Partners' Kemp Doliver flagged integration risk by analogy to Quest's underperforming AmeriPath deal. The transaction closed December 1, 2010 after FTC review (with a divestiture remedy in certain reproductive testing markets). Source: https://www.darkdaily.com/2010/09/15/labcorp-to-acquire-genzyme-genetics-pathology-laboratory-testing-business-for-925-million-915/
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Laboratory Corporation of America Holdings / Genzyme Genetics (business unit) (this deal) | 2010 | $925M | 68 |
| Laboratory Corporation of America Holdings / OPKO Health, Inc. | 2025 | $225M | — |
| Watson Pharmaceuticals (Actavis Inc.) / Actavis plc | 2012 | $5.9B | 97 |
| Kohlberg Kravis Roberts & Co. / PRA International (Genstar Capital) | 2013 | $1.3B | 91 |
| Stryker Corporation / MAKO Surgical Corp. | 2013 | $1.6B | 91 |
| Quintiles Transnational Holdings Inc. / IMS Health Holdings, Inc. | 2016 | $17.6B | 91 |
| DPx Holdings B.V. (JLL Partners 51% / Royal DSM 49%) / Patheon Inc. + DSM Pharmaceutical Products | 2013 | $2.6B | 90 |
← Browse all deals · How we score deals
More: 2010 deals · Other deals